Diagnosis and Management of Fragile X Syndrome

DANIEL J. WATTENDORF, MAJ, MC, USAF, and MAXIMILIAN MUENKE, M.D.,
National Human Genome Research Institute, National Institutes of Health, Bethesda, Maryland

To complement the 2005 Annual Clinical Focus on medical genomics, AFP will be publishing a series of short reviews on genetic syndromes. This series was designed to increase awareness of these diseases so that family physicians can recognize and diagnose children with these disorders and understand the kind of care they might require in the future. The first review in this series discusses fragile X syndrome. (Am Fam Physician 2005;72:111-3. Copyright© 2005 American Academy of Family Physicians.)

Fragile X syndrome is caused by an expansion mutation in the Fragile X mental retardation 1 (FMR1) gene located on the X chromosome. It characteristically leads to some degree of mental retardation. The phenotype is subtle, with minor dysmorphic features and developmental delay during childhood. Characteristic features during adolescence are an elongated face, prominent jaw, large ears, macro-orchidism, and a range of behavioral anomalies and cognitive deficits (Figure 1). Recently recognized manifestations in premutation carriers include premature ovarian failure and tremor/ataxia.1 Premature ovarian failure occurs in up to 20 percent of women who are premutation carriers of the FMR1 gene.1 Fragile X–associated tremor/ataxia syndrome (FXTAS) affects 30 percent of premutation carrier men between the ages of 50 and 60 years, and its prevalence increases with age.1

Epidemiology
Fragile X syndrome, the phenotype associated with full mutation, occurs in approximately one in 4,000 men and one in 6,000 to 8,000 women. The premutation in the FMR1 gene occurs in approximately one in 800 men and up to one in 100 to 200 women. Premutation male carriers are susceptible to FXTAS after age 50. Premature ovarian failure may be detected in as many as one third of women with a premutation.

Clinical Presentation
Although fragile X syndrome occurs in males and females, females generally present with milder symptoms. The first clinical clue in children often is delayed attainment of one or more developmental milestones.2,3 On average, boys with fragile X syndrome sit without support at 10 months of age and walk and talk at 20 months.2 With few exceptions, affected males have mental retardation, generally of moderate degree. About one third of affected females have mild to severe mental retardation.2 There is a specific pattern of deficits in abstract reasoning, sequential processing, and mathematics. Clinical findings during early childhood may include macrocephaly and frontal bossing (unusually prominent forehead). After puberty, macro-orchidism is present in affected men. Additional findings may include strabismus and mild connective tissue dysplasia, such as mitral valve prolapse, hyperextensible joints, and pes planus. Behavior is characterized by attention deficits, hand flapping, hand biting, and gaze aversion. Family physicians are most likely to encounter the undiagnosed child before school age, when formal testing can confirm cognitive deficits. However, the average age of diagnosis currently is eight years, reflecting the subtlety of features in young children.4

FXTAS is a neurodegenerative disorder with progressive intention tremor and cerebellar ataxia.5 Affected persons present with...
parkinsonism, peripheral neuropathies, and dementia after age 50 years.

Premature ovarian failure may occur as an isolated clinical finding in women with pre-
mutations. Follicle-stimulating hormone (FSH) levels are elevated in these women even
before the onset of premature ovarian failure. Approximately 1 percent of women in the
general population have premature ovarian failure, but the prevalence in women with a
premutation is 30 times higher. Women who are infertile and have prematurely elevated
FSH levels should be considered for carrier status testing of the \( FMRI \) pre-
mutation. A family history of FXTAS or premature ovarian failure in a child with cognitive deficits is
another indicator to initiate genetic testing for fragile X syndrome (Figure 2).

**Diagnosis**

The diagnosis of fragile X syndrome is confirmed by molecular genetic testing of the
\( FMRI \) gene. Prenatal testing is available. \( FMRI \) is characterized by a repetitive CGG
trinucleotide sequence, which is repeated six to 50 times in unaffected persons (Figure 2).
A full mutation consists of more than 200 CGG repeats in the \( FMRI \) gene, plus hyper-
methylation, which leads to an inability to produce the \( FMRI \) protein. Almost all males
and more than one half of females with full
mutations have fragile X syndrome. Premu-
tation carriers, who have between 50 and 200
CGG repeats, are not cognitively affected but
may have physical or psychiatric findings. In addition, they are susceptible to develop-
ing premature ovarian failure and FXTAS. Rarely, the fragile X phenotype occurs in
a premutation carrier if hypermethylation is present. Conversely, the phenotype may
be absent in a person with a full mutation without hypermethylation, confirming that
fragile X syndrome results from the absence of \( FMRI \) protein.

**Genetic Counseling and Inheritance**

Fragile X syndrome is an X-linked inherited disorder. It is important to diagnose affected
patients as early as possible to provide early intervention and supportive care (i.e., spe-
cific developmental therapy and an individualized education plan) and to inform
parents for further family planning. One half
of families in a 2002 survey reported having
an additional child with fragile X syndrome before the older affected child was diagnosed.
Family history collection should include
questions about other family members, with
particular attention to developmental delay,
ment retardation, and psychiatric disor-
ders. In addition, a family history of women
with premature ovarian failure and men with
FXTAS should be ascertained. A positive fam-
ily history in a proband with developmental
delay should prompt consideration of genetic
testing of the \( FMRI \) gene. The American
College of Medical Genetics recommends

---

**The Authors**

DANIEL J. WATTENDORF, MAJ, MC, USAF, is a family physician and clinical
geneticist. He is assistant professor in the Department of Family Medicine at the
Uniformed Services University of the Health Sciences, F. Edward Hébert School of
Medicine, Bethesda, Md., and attending clinical geneticist at the National Human
Genome Research Institute, National Institutes of Health (NIH), Bethesda.

MAXIMILIAN MUENKE, M.D., is a pediatrician and clinical geneticist. He is
chief of the Medical Genetics Branch at the National Human Genome Research
Institute, NIH, and director of the medical genetics residency and fellowship
training programs at NIH.

Address correspondence to Dr. Maximilian Muenke, M.D., Medical Genetics
Branch, National Human Genome Research Institute, National Institutes of Health,
35 Convent Dr. – MSC 3717, Building 35, Room 1B-203, Bethesda, MD 20892-3717
(e-mail: mmuenke@nhgri.nih.gov). Reprints are not available from the authors.

---

Figure 1. Dysmorphic findings in persons with
fragile X syndrome include an elongated face,
prominent jaw, and large ears.
testing, regardless of family history, for all males and females with mental retardation of unknown etiology.

**Management**

Treatment is supportive, requiring a multidisciplinary team and including anxiety-reducing measures, behavior modification, and medications to manage associated psychiatric disorders. Individual education plans are necessary for school-age children.

**Resources**

Additional information about the diagnosis and management of fragile X syndrome is available at the following Web sites: National Fragile X Foundation (http://www.FragileX.org); GeneTests (http://www.genetests.org); and the American College of Medical Genetics (www.acmg.net/resources/policies/pol-014.asp).

Author disclosure: Nothing to disclose.

The opinions and assertions contained herein are the private views of the authors and are not to be construed as official or as reflecting the views of the U.S. Air Force Medical Service, the U.S. Air Force at large, the National Human Genome Research Institute, or the National Institutes of Health.

The authors thank Brenda M. Finucane, M.S., Suzanne P. Hart, Ph.D., and Nasreen Malik, M.D., for assistance with the preparation of the manuscript.

Figure 1 used with permission from the National Fragile X Foundation, San Francisco.

Figure 2 provided by Darryl Leja, National Human Genome Research Institute, National Institutes of Health, Bethesda, Md.

This article is one in a series coordinated by the National Human Genome Research Institute, National Institutes of Health, Bethesda, Md. Guest editor of the series is Daniel J. Wattendorf, MAJ, MC, USAF.

**REFERENCES**